Notwithstanding the limited size of a safety trial, we obtained the first evidence of antigen-pulsed tolDC to modulate islet-cell autoimmunity in vivo, predominantly targeting CD4+ T-cell responses and sparing general immune reactivity. Here, CD4 is linked to Autoimmunity.